文献速递炎症性肠病

英夫利昔单抗与乌司奴单抗清除率比谷浓度更能预测克罗恩病内镜结局

Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-09-07

该研究纳入108例接受英夫利昔单抗和80例接受乌司奴单抗治疗的中重度克罗恩病患者,采用贝叶斯预测法估算药物清除率。结果显示,英夫利昔单抗维持期清除率与粪钙卫蛋白对内镜缓解的区分能力相似,而谷浓度在剂量优化后失去预测能力;乌司奴单抗诱导和维持期清除率而非谷浓度与内镜应答显著相关。

要点

  • 英夫利昔单抗维持期清除率可预测w54内镜缓解,谷浓度则不能。
  • 乌司奴单抗诱导和维持期清除率与内镜应答显著相关,谷浓度不相关。
  • 英夫利昔单抗清除率区分内镜缓解的能力与粪钙卫蛋白相似。

核心结论

  • 英夫利昔单抗和乌司奴单抗清除率是预测克罗恩病内镜结局的可靠指标。
  • 谷浓度在剂量优化或非体重给药时失去预测治疗反应的能力。

研究设计与样本

  • 研究重用了108例开始英夫利昔单抗治疗和80例开始乌司奴单抗治疗的中重度克罗恩病患者数据。
  • 采用贝叶斯预测法,结合药物浓度、协变量和内部开发的人群药代动力学模型估算随时间变化的单抗清除率。

主要发现

  • 英夫利昔单抗标准5 mg/kg诱导治疗w2时,达到w12内镜缓解的患者清除率显著更低、谷浓度显著更高(P < .05)。
  • 英夫利昔单抗维持治疗期间,达到w54内镜缓解的患者清除率显著更低(P < .001),但谷浓度无显著差异(P = .92)。
  • 英夫利昔单抗维持期清除率与粪钙卫蛋白区分内镜缓解的AUC相似(0.63;95%CI 0.56-0.69 vs 0.67;95%CI 0.61-0.73)。
  • 乌司奴单抗标准诱导和维持治疗期间,内镜应答者与无应答者的清除率显著不同(P < .05),谷浓度无显著差异。

关键数值与推荐

  • 内镜缓解定义为克罗恩病内镜严重程度指数(CDEIS)<3,于英夫利昔单抗治疗w12和w54评估。
  • 内镜应答定义为克罗恩病简单内镜评分(SES-CD)较基线下降>50%,于乌司奴单抗治疗w24评估。

临床怎么用

  • 在英夫利昔单抗或乌司奴单抗治疗中,可考虑监测药物清除率而非仅依赖谷浓度来预测内镜结局。
  • 剂量优化后谷浓度可能失去预测价值,此时清除率监测可能更有意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Infliximab and ustekinumab clearance have been suggested as predictors of disease activity in patients with inflammatory bowel diseases. We aimed to investigate the benefits of clearance monitoring for predicting endoscopic outcomes in patients with Crohn's disease (CD). METHODS: Data from patients with moderate-to-severe CD starting infliximab (n = 108) and ustekinumab (n = 80) therapy were repurposed. Endoscopic remission (CD Endoscopic Index of Severity <3) was assessed at week (w)12 and w54 of infliximab therapy. Endoscopic response (>50% reduction in Simple Endoscopic Score for CD) was assessed at w24 of ustekinumab therapy. We performed Bayesian forecasting to estimate time-varying mAb clearance using drug concentrations, covariates, and in-house developed population pharmacokinetics models. RESULTS: Patients achieving endoscopic remission at w12 had significantly lower infliximab clearance and higher infliximab serum trough concentrations (Ctrough) at w2 of standard 5 mg/kg infliximab induction therapy, than patients without endoscopic remission (P < .05). During infliximab maintenance therapy (with eventual dose optimizations), patients achieving endoscopic remission at w54 had significantly lower infliximab clearance (P < .001) but not higher infliximab Ctrough (P = .92) than those without remission. Moreover, infliximab clearance during maintenance had similar discriminative ability as fecal calprotectin (area under the receiver operating characteristics curve 0.63; 95% confidence interval, 0.56-0.69 vs 0.67; 95% confidence interval, 0.61-0.73, respectively). Ustekinumab clearance, but not Ctrough, was significantly different between endoscopic responders and nonresponders during standard ustekinumab induction and maintenance therapy (P < .05). CONCLUSIONS: Although Ctrough loses its ability to predict treatment response when doses are optimized or not administered by bodyweight, infliximab and ustekinumab clearance remains a reliable predictor for endoscopic outcomes.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Hoffert Y, Zhang W, et al. Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's Disease. Clin Gastroenterol Hepatol. 2025. PMID: 40925517. doi:10.1016/j.cgh.2025.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。